Soleno Therapeutics Is Trading 63% Below Its Lowest Price Target While a $2.5 Billion Buyer Circles

NEW YORK, April 6 —

Oppenheimer just slashed its Soleno Therapeutics price target from $110 to $80, and somehow that's the bullish read. At $39.49 a share, Soleno trades at a 63% discount to that freshly lowered target, a 62% discount to the $105 consensus, and roughly 20% below the implied per-share value of Neurocrine's reported $2.5 billion acquisition approach. For a company already generating $190 million in trailing revenue with 98.6% gross margins, the market is pricing this like a Phase 2 failure, not a commercial-stage rare disease franchise with a buyer at the door.

What the Street Believes

Wall Street's consensus on Soleno is almost comically bullish on paper. Thirteen analysts carry an average target of $105, implying 166% upside from today's price. Even Oppenheimer, which just delivered the most visible downgrade, kept its Outperform rating and explicitly said Soleno is "seen beating 2026 sales estimates." The thesis is straightforward: Prader-Willi syndrome is a well-defined genetic condition with roughly identifiable patients, Vykat XR is the first targeted therapy for hyperphagia (the relentless, dangerous hunger that defines the disease), and rare disease drugs with no competition tend to find their patients eventually.

But here's what analysts are doing quietly that they're not saying loudly. Oppenheimer didn't just trim a target. It lopped off 27% of its valuation in a single move, from $110 to $80, while insisting the fundamental story hasn't changed. That's the analytical equivalent of saying "the restaurant is great, we just think it has 27% fewer tables than we counted last month." When a firm cuts a target by that magnitude while maintaining a buy rating, they're telling you the launch trajectory they modeled was wrong. The question is whether they've corrected enough.

What the Data Actually Shows

Start with the earnings trajectory, because it tells a story the headline numbers don't. Four quarters ago, Soleno missed estimates by 2.2%, posting a loss of $0.95 per share versus the $0.93 loss expected. Normal early-launch noise. Three quarters ago, the company beat by 80.6%, losing only $0.09 versus the $0.46 loss Wall Street modeled. Then two quarters ago: a $0.47 profit versus the $0.06 expected. That's a 713% beat. The company went from losing money to generating $48 million in free cash flow on a trailing basis. This is not the trajectory of a failed launch.

Oppenheimer adjusts price target on Soleno Therapeutics to $80 from $110, maintains Outperform rating, saying Soleno is seen beating 2026 sales estimates despite slower Vykat XR US launch ramp.

Read that sentence again carefully. Oppenheimer is saying two things simultaneously: the launch is slower than modeled, AND the company will still beat 2026 revenue expectations. Both things can be true if the original models assumed an unrealistically steep initial ramp. Rare disease launches almost never follow the hockey-stick curve that sell-side models love. Patients need genetic confirmation. Doctors need to learn the drug exists. Insurers need to build prior authorization pathways. Each of these steps adds weeks or months. None of them are permanent obstacles.

The 98.6% gross margin tells you everything about the underlying economics. For every dollar of Vykat XR revenue, $0.986 falls to gross profit. This is the margin profile of a rare disease monopoly with zero generic competition. At $190 million in trailing revenue, Soleno is already generating real cash. At the $300-400 million peak sales figures most models assume, this company throws off cash like a tollbooth.

Why This Changes Everything

The math on the Neurocrine deal is where this gets interesting. Reports peg the acquisition approach at roughly $2.5 billion. With the stock at $39.49, Soleno's market cap sits around $2 billion. That means the reported bid represents approximately a 25% premium to the current trading price. In rare disease M&A, premiums of 40-60% over the pre-rumor price are standard because acquirers are buying a permanent revenue stream with no generic cliff. If Neurocrine is offering $2.5 billion now, when launch sentiment is at its lowest, they're buying the dip on purpose.

Think of it this way. Neurocrine is a $14 billion company with deep commercial infrastructure in neuroscience. Prader-Willi syndrome sits squarely in their therapeutic wheelhouse. They're not looking at the same first-quarter prescription data that's spooking public market investors. They're looking at the ten-year revenue stream from the only approved drug for a condition that doesn't go away. The launch slope doesn't matter to an acquirer with a decade-long time horizon. It matters enormously to a hedge fund with a quarterly mark.

If the deal closes near $2.5 billion, shareholders get roughly $46-50 per share, a 17-27% premium from here. If the deal doesn't happen but the launch continues its current trajectory (remember, the company is already FCF positive at $48 million trailing), the analyst consensus of $105 implies the stock needs to nearly triple. Even Oppenheimer's bear-case $80 target means a double from here. The only scenario where $39.49 is the right price is one where both the acquisition collapses AND the launch stalls permanently. That's a parlay bet against a monopoly drug in a genetically defined patient population.

The Bear Case

The bear case deserves real respect here. Prader-Willi syndrome affects an estimated 10,000-20,000 people in the US, and the diagnosed, treatment-eligible population could be meaningfully smaller. If payer pushback is fiercer than expected, with insurers demanding extensive prior authorizations or step therapy before covering Vykat XR, the addressable market shrinks fast. Some rare disease launches have taken five or more years to reach even half their modeled peak, and a few never got there at all.

There's also legitimate deal risk. "Market chatter" about a $2.5 billion acquisition is not a signed merger agreement. Neurocrine could walk away, demand a lower price, or face antitrust complications. Soleno investors who bought at $60 or $70 earlier this year are sitting on painful losses, and the subdued sentiment in the shareholder base is real. If Q2 prescription trends disappoint again without a deal announcement, the stock could drift lower before it goes higher.

But here's why the bear case still doesn't justify $39. The company is already profitable on a free cash flow basis. It has 98.6% gross margins and $190 million in revenue. Even if the launch takes twice as long as bulls expect, the terminal value of a monopoly rare disease drug with these economics is well above $2 billion. You're being asked to bet that a drug already generating meaningful revenue in a population with no alternative treatment will somehow stop growing. That's a tough bet to make.

The Bottom Line

Soleno Therapeutics at $39.49 is priced for a world where the drug launch fails and the acquisition falls apart simultaneously. That's not an investment thesis. That's a panic trade. The reported $2.5 billion Neurocrine approach puts a floor somewhere in the mid-$40s, and the 98.6% gross margin on $190 million in trailing revenue confirms this is a real commercial business, not a clinical-stage hope story. Oppenheimer cut its target by 27% and still sees the stock doubling from here. The risk-reward skews heavily toward the upside for anyone willing to hold through the launch noise. Run the free Soleno Therapeutics, Inc. deep-dive →

What changes my mind: two consecutive quarters of flat or declining prescriptions combined with no deal announcement by late 2026. That would suggest the addressable market is genuinely smaller than modeled, not just slower to capture. Until then, this looks like a rare disease launch following the slow, predictable path that every rare disease launch follows, except this time there's a $2.5 billion buyer standing at the end of it.

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

Why is Soleno Therapeutics stock so far below analyst price targets?

The stock trades at $39.49, well below the $105 consensus target and even below Oppenheimer's recently reduced $80 target. The disconnect stems from investor concern that the Vykat XR launch in the US is ramping more slowly than Wall Street originally modeled. However, the company is already generating $190 million in trailing revenue with 98.6% gross margins and positive free cash flow, suggesting the market may be overreacting to launch timing rather than reflecting a fundamental problem.

What is the reported Neurocrine acquisition of Soleno Therapeutics?

Market reports indicate Neurocrine Biosciences is nearing a roughly $2.5 billion deal to acquire Soleno Therapeutics. At that valuation, shareholders would receive approximately $46-50 per share, a meaningful premium over the current $39.49 price. No formal agreement has been announced, and deal terms could change or the acquisition could fall through entirely.

What is Vykat XR and why does the launch ramp matter?

Vykat XR is the first targeted therapy approved for hyperphagia, the dangerous and uncontrollable hunger associated with Prader-Willi syndrome, a rare genetic condition. The launch ramp matters because analyst price targets are built on assumptions about how quickly the drug reaches patients. Slower early prescriptions have caused some analysts to reduce their peak sales estimates, though Oppenheimer still expects Soleno to beat 2026 sales expectations despite the slower initial trajectory.

Is Soleno Therapeutics profitable?

Yes, on a trailing basis. Soleno generates $48 million in free cash flow with 98.6% gross margins on $190 million in revenue. The company's earnings trajectory has improved dramatically, going from a $0.95 per share loss four quarters ago to a $0.47 per share profit two quarters ago, beating estimates by 713% in its most recent comparable quarter.

What would need to happen for Soleno stock to decline further from here?

The stock at current levels already prices in significant pessimism. For further downside, you would need both the Neurocrine acquisition to fall apart and Vykat XR prescription growth to stall or decline over multiple quarters. That combination would suggest the addressable Prader-Willi patient population is structurally smaller than modeled, not just slower to reach, which would force analysts to cut their peak sales estimates more aggressively.